The S&P 500 Without Big Tech Is Quietly Beating the Full Index in 2026

XMAG (Defiance Large Cap ex-Mag 7 ETF) excludes the Magnificent 7, carries a 0.35% expense ratio, ~$142M AUM, 7% turnover and a trailing dividend yield of 1.2% with only two distributions ($0.047 in Dec 2024; $0.116 in Dec 2025). Year-to-date XMAG is down <1% vs SPY down ~4% and the Roundhill Magnificent Seven ETF down ~12%; trailing 1-year return for XMAG is 13.7% vs SPY 16.2%. The portfolio is overweight IT (21%), financials (16%) and healthcare (14%) with top weights Broadcom 3.85%, JPMorgan 1.94%, Exxon 1.71% and J&J 1.49%; individual dividends are durable but no single position exceeds ~4% of the fund. Conclusion: coherent ex-Mag 7 total-return thesis but a thin income stream (1.2%) and modest AUM/trading-volume raise closure and liquidity risks for income-focused investors.

Analysis

Removing the Magnificent Seven is less a pure ‘‘value’’ pivot and more a redistribution of concentrated idiosyncratic risk into hundreds of mid‑to‑large positions that rarely move the needle individually. That creates two durable mechanics: (1) upward pressure on prices (and compression of yields) for a large swath of corporates that receive steady ETF inflows, and (2) elevated idiosyncratic liquidity risk when flows reverse — forced selling of thinly traded names can cascade faster than headline active managers can absorb.

The dominant short‑term catalyst is positioning and narrative, not fundamentals; a renewed AI or megacap earnings surge could quickly re‑load the Magnificent Seven and unwind dispersion trades within weeks, while a pause in that narrative favors relative strength for cyclicals and cash‑generative banks/energy over months. Monitor two observables as early warning signals: (a) breadth of daily volume concentration (top 7 vs rest) and (b) options skew/put buying in megacaps — regime flips show up there before price.

Consensus mistake: treating ex‑Mag7 exposures as ‘‘no‑tech’’ or low‑beta. In practice, residual AI/enterprise exposure via large suppliers and incumbents (semicap suppliers, enterprise software, telecom infrastructure) leaves the bucket sensitive to the same narrative moves — upside is capped, downside is non‑linear if megacaps re‑accelerate. That argues for tactical, hedged exposure and preferring direct ownership of durable payers over passive, small‑AUM vehicles when targeting income or risk‑adjusted yield.

Key Decisions for Investors

• Pair trade (3–6 months): Short a concentrated Mag7 basket (focus on NVDA, MSFT, AAPL) sized to 2% notional risk vs long AVGO + XOM + JPM equally weighted. Target 8–12% relative return; stop and reduce if the Mag7 basket rallies 8% absolute from entry or if implied vol on NVDA contracts rises >25% signaling renewed AI repricing.
• Income overlay (1–3 months rolling): Accumulate JPM and XOM outright and sell 3‑month covered calls 10–15% OTM to harvest ~4–6% incremental income pa in roll terms. Risk: keep max position size per name to 3% portfolio and cut if share price drops >12% or dividend guidance weakens.
• Tail hedge for ex‑Mag7 exposure (0.5–2% cost target): Buy a 3‑month put spread on NVDA (10%/20% OTM) sized to cover 25–50% of notional exposure to the Mag7 risk. This caps hedging cost while protecting against a concentrated AI re‑rate that would hurt long ex‑Mag7 positions.
• Execution/positioning rule: Avoid >2% portfolio allocation to any single small‑AUM passive ex‑Mag7 ETF; instead build income exposure from direct names with liquid options markets (JPM, XOM, JNJ, AVGO) to control carry, liquidity and closure risk over 6–18 months.